Skip to main content

Table 3 Relationship between PLRs and clinical factors

From: An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer

Factor pPLR (+) pPLR (−) P-value iPLR (+) iPLR (−) P-value fPLR (+) fPLR (−) P-value
Sex(M/F) 32/18 41/ 9 0.070 39/11 34/16 0.368 24/11 49/16 0.486
Age (< 65/≥65 years) 24/26 17/33 0.222 21/29 20/30 1.000 15/20 26/39 0.833
Tumor size (< 60/≥60 mm) 21/29 27/23 0.317 26/24 22/28 0.548 15/20 33/32 0.531
Histologic type (Diff/Undiff) 15/35 20/30 0.402 19/31 16/34 0.675 8/27 27/38 0.080
pT (1/2/3/4) 0/ 6/16/28 5/ 6/25/14 0.006* 4/ 8/21/17 1/ 4/20/25 0.210 3/ 5/11/16 2/ 7/30/26 0.393
pN (0/1/2/3) 4/13/12/21 10/12/19/ 9 0.030 8/15/16/11 6/10/15/19 0.332 4/ 6/13/12 10/19/18/18 0.480
pStage (II/III) 12/38 27/23 0.004* 25/25 14/36 0.040 13/22 26/39 0.832
Lymphatic invasion (+/−) 42/ 8 38/12 0.454 39/11 41/ 9 0.803 26/ 9 54/11 0.307
Venous invasion (+/−) 39/11 39/11 1.000 38/12 40/10 0.810 25/10 53/12 0.312
Recurrence (+/−) 19/31 16/34 0.675 14/36 21/29 0.208 15/20 20/45 0.274
Outcome (D/A) 16/34 8/42 0.100 10/40 14/36 0.483 14/21 10/55 0.013
  1. M, male; F, female; Diff, differentiated type; Undiff, undifferentiated type; pT, pN, pStage = pathological T stage, N stage. Pathological cancer stage according to the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual; pPLR, preoperative platelet-to-lymphocyte ratio; iPLR, the ratio of the PLR on the initial day of adjuvant chemotherapy to pPLR; fPLR, the ratio of the PLR on the final day of adjuvant chemotherapy to iPLR; D/A, dead or alive; *P-value indicates statistical significance after false discovery rate correction
\